Compare Alcon AG (ALC) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs ProShares Ultra Gold ETF — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while ProShares Ultra Gold ETF trades at $44.68. The key difference: Alcon AG pays a 0.54% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals.
| ALC | UGL | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.22 | $85.62 |
52-Week Low | $62.02 | $33.59 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
UGL trades at $47.09, up 2.04% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights strong central bank gold buying and analyst optimism for gold prices, which may indirectly influence gold-related equities.
The outlook is cautious due to bearish technicals and absent financial data. Risks include gold price volatility and macroeconomic factors. Investors should await earnings reports for fundamental insights, as current data is insufficient for a clear investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
